RU2018131622A3 - - Google Patents

Download PDF

Info

Publication number
RU2018131622A3
RU2018131622A3 RU2018131622A RU2018131622A RU2018131622A3 RU 2018131622 A3 RU2018131622 A3 RU 2018131622A3 RU 2018131622 A RU2018131622 A RU 2018131622A RU 2018131622 A RU2018131622 A RU 2018131622A RU 2018131622 A3 RU2018131622 A3 RU 2018131622A3
Authority
RU
Russia
Application number
RU2018131622A
Other languages
Russian (ru)
Other versions
RU2732502C2 (ru
RU2018131622A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018131622A publication Critical patent/RU2018131622A/ru
Publication of RU2018131622A3 publication Critical patent/RU2018131622A3/ru
Application granted granted Critical
Publication of RU2732502C2 publication Critical patent/RU2732502C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56933Mycoplasma
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/5695Mycobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/44Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
RU2018131622A 2016-02-10 2017-02-01 Новые моноклональные антитела к LAM и PIM6/LAM для диагностики и лечения инфекций, вызванных Mycobacterium tuberculosis RU2732502C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662293406P 2016-02-10 2016-02-10
US62/293,406 2016-02-10
PCT/US2017/016058 WO2017139153A1 (en) 2016-02-10 2017-02-01 Novel anti-lam and anti-pim6/lam monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections

Publications (3)

Publication Number Publication Date
RU2018131622A RU2018131622A (ru) 2020-03-10
RU2018131622A3 true RU2018131622A3 (enExample) 2020-04-13
RU2732502C2 RU2732502C2 (ru) 2020-09-18

Family

ID=59563993

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018131622A RU2732502C2 (ru) 2016-02-10 2017-02-01 Новые моноклональные антитела к LAM и PIM6/LAM для диагностики и лечения инфекций, вызванных Mycobacterium tuberculosis

Country Status (10)

Country Link
US (4) US10729771B2 (enExample)
EP (2) EP4299072A3 (enExample)
JP (4) JP2019506412A (enExample)
CN (2) CN109073649A (enExample)
AU (2) AU2017218415B2 (enExample)
CA (1) CA3013904C (enExample)
ES (1) ES2970828T3 (enExample)
RU (1) RU2732502C2 (enExample)
WO (1) WO2017139153A1 (enExample)
ZA (3) ZA201805990B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017218415B2 (en) 2016-02-10 2024-05-02 Rutgers, The State University Of New Jersey Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections
US10830760B2 (en) * 2017-12-20 2020-11-10 General Electric Company Device for rapid detection of tuberculosis-lipoarabinomannan (TB-LAM) with enhanced sensitivity
WO2019186486A1 (en) * 2018-03-29 2019-10-03 Foundation Of Innovative New Diagnostics Antibody or antibody combination and method using same for detection of an antigen related to mycobacterium in a urine sample of a subject
WO2020018806A1 (en) 2018-07-19 2020-01-23 Rutgers, The State University Of New Jersey Methods for dual detection and differentiation of infection by mycobactierum tuberculosis complex and nontuberculous mycobacteria
WO2020045625A1 (ja) 2018-08-31 2020-03-05 富士フイルム株式会社 イムノクロマトグラフキットおよび結核菌の検出方法
WO2021065144A1 (ja) 2019-09-30 2021-04-08 富士フイルム株式会社 イムノクロマトグラフィー
CN114341639A (zh) 2019-09-30 2022-04-12 富士胶片株式会社 免疫检查方法及浓缩用夹具
CN111337665A (zh) * 2020-01-16 2020-06-26 卢氏实验室公司 一种用于检测肺结核感染的免疫层析试纸条及其制备方法
WO2021153127A1 (ja) 2020-01-31 2021-08-05 富士フイルム株式会社 免疫検査方法
JP7257556B2 (ja) 2020-01-31 2023-04-13 富士フイルム株式会社 イムノクロマトグラフィー
JP7350100B2 (ja) 2020-01-31 2023-09-25 富士フイルム株式会社 イムノクロマトグラフィー
CN111153992A (zh) * 2020-02-21 2020-05-15 首都医科大学附属北京胸科医院 结核分枝杆菌lam的单克隆抗体及其用途
WO2022011001A1 (en) * 2020-07-07 2022-01-13 The Regents Of The University Of California Method for antigen detection from direct clinical samples
EP4192429A4 (en) * 2020-08-05 2024-10-09 The Administrators of The Tulane Educational Fund METHOD FOR DETECTING TB IN BODY FLUID SAMPLES
EP4212873A4 (en) 2020-09-11 2024-06-05 FUJIFILM Corporation CONCENTRATION DEVICE, METHOD FOR CONCENTRATING A SAMPLE SOLUTION, METHOD FOR TESTING A SAMPLE SOLUTION AND TEST KIT
WO2022054524A1 (ja) 2020-09-11 2022-03-17 富士フイルム株式会社 濃縮デバイス、検体液の濃縮方法、検体液の検査方法、及び、検査キット
CN116171378A (zh) 2020-09-11 2023-05-26 富士胶片株式会社 被检体液的浓缩方法、及被检体液的检查方法
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules
EP4263598A4 (en) * 2020-12-15 2025-04-09 Albert Einstein College of Medicine High-affinity mycobacterium tuberculosis capsule-specific human monoclonal antibodies
CN113480659B (zh) * 2021-06-30 2022-10-21 迪比康(上海)生物科技有限公司 人源抗结核分枝杆菌复合群lam单克隆抗体及其制备和应用
CN114984870A (zh) * 2022-03-15 2022-09-02 齐欣 一种重组蛋白质微球及其制备方法和应用
CN117247450B (zh) * 2023-10-10 2025-02-25 广州市雷德生物科技有限公司 一种lam抗体及其应用
CN118178640B (zh) * 2024-03-08 2025-11-21 中国农业大学 含有牛分枝杆菌表面多糖的佐剂及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
JPH09505308A (ja) 1993-11-19 1997-05-27 アルカーミズ・コントロールド・セラピューティクス・インコーポレイテッド・トゥー 生物学的活性剤を含有する生分解性微粒子の製造
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US20010007660A1 (en) * 1997-06-04 2001-07-12 Aharona Glatman-Freedman Methods of treating and protecting against tuberculosis using a monoclonal antibody selective for mycobacterium tuberculosis
EP1028746B1 (en) 1997-11-07 2003-02-26 Chiron Corporation Method for producing igf-i sustained-release formulations
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6953593B2 (en) 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
WO2002085335A1 (en) 2001-04-18 2002-10-31 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US7063725B2 (en) 2002-10-21 2006-06-20 Sdgi Holdings, Inc. Systems and techniques for restoring and maintaining intervertebral anatomy
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US20050187631A1 (en) 2004-01-27 2005-08-25 Sdgi Holdings, Inc. Prosthetic device
UA92721C2 (ru) * 2004-07-20 2010-12-10 Чемоджен, Инк. Обогащенная популяция антител, высокоспецифических к антигену поверхностного полисахарида липоарабиноманана (lam) микобактерии, способ выявления микобактериальной инфекции в образце и набор для выявления микобактериальной инфекции
CN101216491B (zh) * 2008-01-08 2012-06-06 广州益善生物技术有限公司 结核分枝杆菌检测液相芯片及其制备方法
EP2242836B1 (en) * 2008-01-28 2015-05-20 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
AU2009294414A1 (en) 2008-09-19 2010-03-25 Medimmune Llc Antibodies directed to CD105 and uses thereof
WO2011013698A1 (ja) * 2009-07-29 2011-02-03 東亞合成株式会社 キャリアペプチドフラグメント及びその利用
US9315566B2 (en) * 2011-01-24 2016-04-19 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
DK2821415T3 (da) * 2012-02-29 2021-04-26 Otsuka Pharma Co Ltd Antistof mod anti-lipoarabinomannan og immunoassay til syrefast bacillær infektion under anvendelse af antistoffet
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
AU2017218415B2 (en) 2016-02-10 2024-05-02 Rutgers, The State University Of New Jersey Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections

Also Published As

Publication number Publication date
RU2732502C2 (ru) 2020-09-18
RU2018131622A (ru) 2020-03-10
CN109073649A (zh) 2018-12-21
ZA202307912B (en) 2025-11-26
JP7316685B2 (ja) 2023-07-28
BR112018016226A2 (pt) 2019-01-02
US12303562B2 (en) 2025-05-20
EP3414573A4 (en) 2019-10-30
US11707525B2 (en) 2023-07-25
EP3414573B1 (en) 2023-11-08
JP2024174883A (ja) 2024-12-17
ZA202209045B (en) 2023-12-20
JP2019506412A (ja) 2019-03-07
EP4299072A2 (en) 2024-01-03
JP2021105034A (ja) 2021-07-26
ES2970828T3 (es) 2024-05-30
EP3414573A1 (en) 2018-12-19
US20220168420A1 (en) 2022-06-02
EP4299072A3 (en) 2024-05-01
US10729771B2 (en) 2020-08-04
WO2017139153A1 (en) 2017-08-17
CN110092830B (zh) 2023-07-04
US20200316199A1 (en) 2020-10-08
US20240307535A1 (en) 2024-09-19
CA3013904C (en) 2023-12-12
ZA201805990B (en) 2023-01-25
BR112018016226A8 (pt) 2023-10-24
CA3013904A1 (en) 2017-08-17
JP2023075196A (ja) 2023-05-30
US20190038747A1 (en) 2019-02-07
US11273220B2 (en) 2022-03-15
AU2024205286A1 (en) 2024-08-22
AU2017218415B2 (en) 2024-05-02
CN110092830A (zh) 2019-08-06
AU2017218415A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
BR112019009191A2 (enExample)
BR112019002665A2 (enExample)
BR112019008128A2 (enExample)
BR112019001685A2 (enExample)
BR202016008885U2 (enExample)
BR202016005183U2 (enExample)
CN303537333S (enExample)
CN303537519S (enExample)
CN303536206S (enExample)
CN303536229S (enExample)
CN303536236S (enExample)
CN303613505S (enExample)
CN303536258S (enExample)
CN303536391S (enExample)
CN303536426S (enExample)
CN303536494S (enExample)
CN303536529S (enExample)
CN303536541S (enExample)
CN303536593S (enExample)
CN303536622S (enExample)
CN303536638S (enExample)
CN303537266S (enExample)
CN303537289S (enExample)
CN303537328S (enExample)
CN303621594S (enExample)